Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mitsui DM Sugar Holdings, the corporate successor to Dainippon Sugar Manufacturing, is a leading Japanese producer of sugar and health-related functional ingredients. While its core business is sugar refining, the company maintains a significant presence in the life sciences sector through its development of physiological functional carbohydrates and pharmaceutical excipients. Its flagship product, Palatinose (isomaltulose), is a slow-release carbohydrate used extensively in clinical nutrition and sports medicine to manage blood glucose levels. The company also manufactures high-purity sucrose and other specialized ingredients that serve as critical excipients for the pharmaceutical industry. Through its biotechnology research, Mitsui DM Sugar focuses on the "Slow Calorie" concept to address metabolic health and obesity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dainippon Sugar Manufacturing.